Xerostomia Dry Mouth Disease Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.25 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Xerostomia Dry Mouth Disease Therapeutics Market Analysis
The Xerostomia (Dry Mouth Disease) Therapeutics market is projected to register a CAGR of 4.25% during the forecast period (2022-2027).
The COVID-19 pandemic has posed new challenges in every aspect of an individual's life, including oral health. Dry mouth has become one of the most common problems that patients from all walks of life are dealing with. COVID-19 has also been linked to dry mouth as a symptom. According to the article titled "Xerostomia (dry mouth) in patients with COVID-19: a case series" published in April 2021, dry mouth appeared in 60% of cases 3-4 days before as a prodromal symptom and in others, simultaneously or 1-2 days after the onset of other symptoms. In the majority of cases, dry mouth improved over time after beginning treatment. The study further stated that in COVID-19 patients, xerostomia may develop before the onset of the common symptoms. Such studies demonstrate the frequency of the condition in COVID-19 patients and hence suggest that the demand for therapeutics for dry mouth disease is anticipated to grow in the near future. Thus, COVID-19 is expected to have a pronounced effect on the growth of the market.
Xerostomia commonly referred to as "dry mouth syndrome", is a result of reduced or absent salivary flow, producing mucosal dryness. The increase in radiation therapy and chemotherapy is likely to lead to an increased incidence of xerostomia, which is estimated to predominantly drive the xerostomia therapeutics market. Other factors driving the market growth include increasing usage of prescription medicines; easy availability and cost-effectiveness of medicines; a growing geriatric population base; and increasing prevalence of diseases, such as Sjogren's syndrome, HIV, diabetes, and Alzheimer's disease, among other diseases.
Additionally, the geriatric population is expected to have a significant impact on the market studied. For instance, according to the World Population Prospect, 2022, globally, in 2022, there were 771 million people aged 65 years or over, and it is projected to reach 994 million by 2030 and 1.6 billion by 2050. Elderly people frequently experience xerostomia, which is typically associated with reduced salivary gland activity. The use of drugs, chronic illnesses, and radiation therapy to the head and neck region have all been implicated as causes of xerostomia in the elderly population.
Furthermore, according to the International Diabetes Federation, as of 2021, there are 536.6 million people aged 20 -79 years around the world living with diabetes, and this number is expected to reach 783.7 million by 2045. Diabetes is often associated with dry mouth syndrome. For instance, as per the article titled "Xerostomia, Salivary Flow, and Oral Health Status Among Saudi Diabetic Patients: A Comparative Cross-Sectional Study" published in the National Library of Medicine in November 2021, Xerostomia was one of the symptoms of diabetes that was most frequently reported. In diabetic patients, xerostomia can occur anywhere between 12.5% and 76.4% of the time. Further, the study detailed that the data from the cross-sectional investigation of 50 diabetic patients in Saudi Arabia was collected, wherein 52% of controls and 60% of the diabetic participants both exhibited xerostomia. Thus, the growing burden of diseases leading to xerostomia is expected to drive the growth of the market.
Thus, the market is expected to experience significant growth over time. However, factors, such as lack of awareness and unavailability of effective treatment, are likely to hinder the usage of xerostomia therapeutics products and can act as a restraining factor for the xerostomia therapeutics market.
Xerostomia Dry Mouth Disease Therapeutics Market Trends
This section covers the major market trends shaping the Xerostomia (Dry Mouth Disease) Therapeutics Market according to our research experts:
Artificial Saliva/Saliva Substitutes Segment Expected to Dominate the Market Over the Forecast Period
The reduction of saliva in the mouth can lead to tooth decay, mouth infections, an altered sense of taste or smell, difficulty in swallowing, pain, and many other complications. Artificial saliva is a liquid or aerosol product that is sprayed into the mouth. They are designed to moisten and relieve the pain and discomfort of chronic dry mouth, especially with regular use. Many artificial saliva sprays and gels claim to work for up to two hours, and many users require more frequent applications to maintain moisture in the mouth, which can greatly interfere with sleep and daily activity. Several saliva sprays and gels also have a reputation for strong and unpleasant flavors, though a recent increase in the use of naturally sweet xylitol has led to the availability of better alternatives.
Factors such as the growing burden of dry mouth disease and increasing research studies are propelling the growth of the market segment. For instance, the article titled "Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed Versus Placebo" published in July 2020, concluded that the use of Aldiamed spray was shown to be more effective than a placebo in the treatment of xerostomia in type 1 and type 2 diabetes. Such studies demonstrate that saliva substitutes are effective for the treatment of xerostomia. The mentioned source also reported that the dry mouth symptom is one of the most common oral complaints in patients with diabetes mellitus. Moreover, the prevalence of xerostomia and hyposalivation has been reported to increase with age. The study also projects that there may be increasing demand for saliva substitutes in the coming years as the burden of diabetes mellitus and the geriatric population is expected to show rapid growth in the near future.
Hence, owing to the aforementioned factors, along with the rising disease burden and availability of over-the-counter artificial saliva products, the segment is expected to register steady growth during the forecast period.
Asia-Pacific is Expected to be the Fastest Growing Region Over the Forecast Period
The Asia-Pacific region is expected to register lucrative growth over the forecast period due to factors such as growing healthcare expenditure, an increase in initiatives for raising awareness, and the rising prevalence of diseases such as diabetes, HIV, cancer, and Parkinson's disease that cause dry mouth conditions.
Cancer rates are increasing drastically in the Asia-Pacific region. For instance, according to GLOBOCAN 2020, there are 9,386,454 new cases of cancer in Asia, and it is projected to reach 14,229,878 by 2040. Emerging economies, such as China and India, have adopted both health and industrial policies to encourage the domestic production of cancer drugs, which is leading to lower therapy costs. Lower therapy costs, coupled with increasing awareness about cancer, are leading to higher adoption of chemotherapy and radiotherapy. The increasing burden of cancer leads to greater adoption of radiotherapy and chemotherapy, along with the dry mouth conditions associated with the treatments. Thus, this creates the need for therapeutics for treating xerostomia, which ultimately boosts the market growth in the region.
Also, as per the article titled "An Update on the Lived Experience of Dry Mouth in Sj枚gren's Syndrome Patients" published in November 2021, dry mouth is a significant condition that impacts the daily lives of people with Sj枚gren's Syndrome (SS). As per the same source, in the Sj枚gren's International Collaborative Clinical Alliance (SICCA) registry of 1578 SS participants, 90% reported symptoms of dry mouth. Furthermore, the article titled "Analysis of medication-induced xerostomia in elderly Japanese patients", published in September 2021, stated that the risk of xerostomia also increases with age as the number of medications the elderly population consumes tends to increase. Hence, the increasing prevalence of chronic diseases results in the increased use of medications, thereby resulting in dry mouth.
Thus, the aforesaid factors are likely to boost the growth of the market in the Asia-Pacific region.
Xerostomia Dry Mouth Disease Therapeutics Industry Overview
The xerostomia therapeutics market is moderately competitive. Key players in the xerostomia (dry mouth disease) therapeutics market are focusing on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. Some of the key players dominating the xerostomia therapeutics market are 3M, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, Parnell Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., and Synedgen, among others.
Xerostomia Dry Mouth Disease Therapeutics Market Leaders
-
GlaxoSmithKline PLC
-
Parnell Pharmaceuticals Inc.
-
Bausch Health Companies Inc.
-
3M company
-
Quest Products Inc.
*Disclaimer: Major Players sorted in no particular order
Xerostomia Dry Mouth Disease Therapeutics Market News
- In September 2021, ICPA Health Products (ICPA) introduced Wet Mouth, a saliva substitute for treating individuals suffering from xerostomia, commonly known as dry mouth.
- In February 2021, Virginia Head and Neck Therapeutics, Inc., launched Voutia, which provides continuous relief from xerostomia (commonly known as chronic dry mouth). The patented, FDA-cleared device offers an entirely new approach for millions of people suffering from this uncomfortable and often debilitating condition.
Xerostomia Dry Mouth Disease Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
4.2.3 Rising Burden of Diseases, such as Sjogren's Syndrome, HIV, Diabetes, Alzheimer's disease, and Other Diseases
4.3 Market Restraints
4.3.1 Lack of Awareness of Xerostomia in Developing and Underdeveloped Economies
4.3.2 Unavailability of Effective Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Artificial Saliva/Saliva Substitutes
5.1.2 Salivary Stimulants
5.2 By Product
5.2.1 Drugs
5.2.2 Salivary Pens
5.2.3 Other Product Types
5.3 By Distribution Channel
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacy
5.3.3 Online Pharmacy
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Quest Products Inc.
6.1.2 Fresenius SE & Co. KGaA
6.1.3 GlaxoSmithKline PLC
6.1.4 Hikma Pharmaceuticals PLC
6.1.5 Lupin Limited
6.1.6 Pharmascience Inc (Pendopharm)
6.1.7 Parnell Pharmaceuticals Inc.
6.1.8 Sun Pharmaceutical Industries Ltd
6.1.9 Synedgen Inc. (Prisyna)
6.1.10 ADVANZ PHARMA Corp. Limited
6.1.11 Saliwell Ltd
6.1.12 3M company
6.1.13 Sanofi (Chattem, Inc.)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Xerostomia Dry Mouth Disease Therapeutics Industry Segmentation
As per the scope of the report, Xerostomia is defined as a dry mouth, resulting from reduced or absent saliva flow. It is not a disease, but it could be a symptom of various medical conditions, a side effect of radiation to the head and neck, or a side effect caused by a wide variety of medications. It may or may not be associated with decreased salivary gland function. The Xerostomia (Dry Mouth Disease) Therapeutics Market is Segmented by Type (Artificial Saliva/Saliva Substitutes, and Salivary Stimulants), Product (Drugs, Salivary Pens, and Other Product Types), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type | |
| Artificial Saliva/Saliva Substitutes | |
| Salivary Stimulants |
| By Product | |
| Drugs | |
| Salivary Pens | |
| Other Product Types |
| By Distribution Channel | |
| Hospital Pharmacy | |
| Retail Pharmacy | |
| Online Pharmacy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Xerostomia Dry Mouth Disease Therapeutics Market Research FAQs
What is the current Global Xerostomia (Dry Mouth Disease) Therapeutics Market size?
The Global Xerostomia (Dry Mouth Disease) Therapeutics Market is projected to register a CAGR of 4.25% during the forecast period (2024-2029)
Who are the key players in Global Xerostomia (Dry Mouth Disease) Therapeutics Market?
GlaxoSmithKline PLC, Parnell Pharmaceuticals Inc., Bausch Health Companies Inc., 3M company and Quest Products Inc. are the major companies operating in the Global Xerostomia (Dry Mouth Disease) Therapeutics Market.
Which is the fastest growing region in Global Xerostomia (Dry Mouth Disease) Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Xerostomia (Dry Mouth Disease) Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Xerostomia (Dry Mouth Disease) Therapeutics Market.
What years does this Global Xerostomia (Dry Mouth Disease) Therapeutics Market cover?
The report covers the Global Xerostomia (Dry Mouth Disease) Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Xerostomia (Dry Mouth Disease) Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Xerostomia Dry Mouth Disease Therapeutics Industry Report
The Global Xerostomia Dry Mouth Disease Therapeutics Market report provides a comprehensive industry overview, covering key aspects such as market segmentation by type, product, distribution channel, and geography. The market analysis includes insights into the market growth, market value, and market outlook, offering a detailed market forecast and industry outlook.
The report highlights the significance of artificial saliva, saliva substitutes, and salivary stimulants in the market, along with the role of drugs, salivary pens, and other product types. The distribution channels analyzed include hospital pharmacy, retail pharmacy, and online pharmacy, providing a thorough market review and industry statistics across North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Industry reports indicate the market leaders and market trends, emphasizing the market growth rate and industry size. The report also includes market predictions, industry sales, and industry trends, supported by market data and industry research.
This industry analysis is crucial for understanding the market segmentation and market value, offering a detailed market overview and industry information. The report example and report PDF provide additional insights, making it a valuable resource for research companies and stakeholders.
Overall, the market forecast and industry reports provide a robust foundation for understanding the dynamics of the Xerostomia Dry Mouth Disease Therapeutics market, ensuring informed decision-making and strategic planning.
